STOCK TITAN

Sage Therapeutics Inc - SAGE STOCK NEWS

Welcome to our dedicated news page for Sage Therapeutics (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sage Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sage Therapeutics's position in the market.

Rhea-AI Summary
Sage Therapeutics reports encouraging early launch results for ZURZUVAE, the first oral treatment for postpartum depression, achieving $0.8 million in collaboration revenue. The company anticipates significant value creation in 2024 with multiple data read-outs. Financially, Sage ended 2023 with $753 million in cash, cash equivalents, and securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.86%
Tags
earnings
-
Rhea-AI Summary
Sage Therapeutics, Inc. (NASDAQ: SAGE) will host a live webcast to review fourth quarter and full year 2023 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences earnings
-
Rhea-AI Summary
Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the upcoming launch of ZURZUVAE™ (zuranolone), the first oral treatment for adults with postpartum depression (PPD) in December 2023. The company also highlighted progress on clinical pipeline with topline data expected from multiple ongoing Phase 2 trials across 2024, positioning itself for a catalyst-rich year supported by a strong financial foundation and focused execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.91%
Tags
none
Rhea-AI Summary
Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the retirement of Kevin Starr from the company's board of directors. Geno Germano has assumed the role of Chair of the Board of Directors. Mr. Starr co-founded Third Rock Ventures in 2007 and was a leader in the formation, development, and business strategy of the firm's portfolio companies. Geno Germano, the new Chair of the Board, has over 30 years of experience in the pharmaceutical industry and a consistent track record of improving operating performance and increasing shareholder value across numerous leadership roles in multiple therapeutic categories and global markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.91%
Tags
management
-
Rhea-AI Summary
Sage Therapeutics, Inc. (NASDAQ: SAGE) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 4:30 p.m. PT in San Francisco, CA. The live webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com, with a replay available for up to 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
conferences
-
Rhea-AI Summary
Sage Therapeutics, Inc. (NASDAQ: SAGE) announces participation in Stifel 2023 Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference in November. The company will have fireside chats on November 15th and November 30th, respectively. A live webcast and replay of each event will be available on the Investor page of Sage’s website at investor.sagerx.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
conferences
Rhea-AI Summary
Sage Therapeutics reported business highlights and financial results for the third quarter ended September 30, 2023. The company announced the expected wholesale acquisition cost of ZURZUVAE to be $15,900, with the product becoming commercially available in December 2023. Sage also provided updates on their neuropsychiatry pipeline, including the progress of SAGE-718 and SAGE-324. Financially, the company's cash, cash equivalents, and marketable securities totaled $876 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
earnings
-
Rhea-AI Summary
Sage Therapeutics to host webcast to review Q3 2023 financial results and business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
conferences earnings
-
Rhea-AI Summary
Sage Therapeutics receives FDA Orphan Drug Designation for SAGE-718 in the treatment of Huntington's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
clinical trial
Rhea-AI Summary
Sage Therapeutics to present at investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
Sage Therapeutics Inc

Nasdaq:SAGE

SAGE Rankings

SAGE Stock Data

1.36B
47.55M
12.52%
95.97%
13.07%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SAGE

sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.